CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis

SIMPLE SUMMARY: Up to 50% of patients with chronic lymphocytic leukemia relapse within four years after anti-CD20-directed treatment with a need for a subsequent treatment, which can potentially include anti-CD20 agents again. To retrospectively study the influence of CD20 expression in CLL patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Schilhabel, Anke, Walter, Peter Jonas, Cramer, Paula, von Tresckow, Julia, Kohlscheen, Saskia, Szczepanowski, Monika, Laqua, Anna, Fischer, Kirsten, Eichhorst, Barbara, Böttcher, Sebastian, Schneider, Christof, Tausch, Eugen, Brüggemann, Monika, Kneba, Michael, Hallek, Michael, Ritgen, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562902/
https://www.ncbi.nlm.nih.gov/pubmed/36230840
http://dx.doi.org/10.3390/cancers14194917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562902/
https://www.ncbi.nlm.nih.gov/pubmed/36230840
http://dx.doi.org/10.3390/cancers14194917

Ejemplares similares